Background: The efficacy of prevention of perinatal transmission of HIV-1 is dependent on both viral load and treatment duration. The objective of this study was to determine whether initiating highly active antiretroviral treatment (HAART) before conception has the potential to eliminate perinatal transmission.
Methods: In the national prospective multicentre French Perinatal Cohort (EPF), perinatal transmission (PT) was analysed according to the viral load (VL) in maternal plasma near delivery and timing of HAART initiation in 7937 HIV-infected women from 2000 to 2011.
Results: The overall incidence of PT was 56/7937 (0.7%). No case of transmission occurred among the 2588 women who were on HAART before conception, without treatment interruption during the first trimester, and who delivered with a plasma VL <50 copies /mL (upper 95% confidence interval limit: 0.1%).
VL and timing of HAART initiation were independently associated with PT in logistic regression (Fig 1). Regardless of viral load, the transmission rate increased from 0.2% for women initiating HAART prior to conception to 0.4% during the 1st trimester, 0.9% during the 2nd trimester and 2.2% during the 3rd trimester; p<0.001. Regardless of timing of HAART initiation, the rate was higher for women with VL between 50 and 400 copies/mL near delivery than for those with < 50 copies/mL: adjusted odds ratio = 3.5 [95%CI: 1.7 -7.3].
Conclusions: Perinatal HIV-1 transmission is virtually zero in mothers who start antiretroviral therapy before conception and maintain suppression of the plasma viral load.